ArticleGynecologic oncology reports2020

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035).

Elizabeth K Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.